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Burkholderia cepacia complex isolates obtained by microbiological culture of respiratory samples from Brazilian CF patients were studied by
recA based PCR, screened by specific PCR for virulence markers and genotyped by RAPD. Forty-one isolates of B. cepacia complex were
identified by culture and confirmation of identity and genomovar determination obtained in 32 isolates, with predominance of B. cenocepacia
(53.1%). Virulence markers were not consistently found among isolates. Genotyping did not identify identical patterns among different patients.
B. cenocepacia was the most prevalent B. cepacia complex member among our patients, and cross-infection does not seem to occur among them.
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The Burkholderia cepacia complex has been recognized as a
significant pathogen for CF patients since the early 1980s and
consists of ten closely related species, also called genomovars
[1]. Most specialized centres report a prevalence of B. cepacia
complex of up to 10% [2–4]. B. cenocepacia is a member of the
B. cepacia complex showing the highest prevalence among CF
patients, followed by B. multivorans, although regional
differences in genomovar distribution have been reported [5].
Highly transmissible strains of the B. cepacia complex have
been identified in some CF centres, mainly in the United⁎ Corresponding author. Pediatric Pulmonology Unit, Instituto da Criança
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doi:10.1016/j.jcf.2007.12.001Kingdom and Canada, and genetic markers including cable
pilus gene (cblA) and an insertion sequence named B. cepacia
epidemic strain marker (BCESM) are commonly detected in
these strains [6,7].
There is little published data regarding prevalence and
genomovar distribution of B. cepacia complex strains isolated
from Brazilian cystic fibrosis patients [8–10]. The Pediatric
Pulmonology Unit of Instituto da Criança is one of the referral
centres for CF care in Brazil and, although segregation of
patients based on respiratory colonization has not been
implemented to date, cross-colonization with P. aeruginosa
strains has not been identified among patients [11]. The
objective of the present study was to analyse B. cepacia
complex strains isolated from CF patients attending our CF
centre, by determining genomovar distribution, virulence-
related genetic markers and the genotype of these isolates for
epidemiological purposes.d by Elsevier B.V. All rights reserved.
Table 1
Genomovar determination by PCR, recA gene DNA sequencing and RAPD
genotyping of isolates identified as members of the B. cepacia complex during
the study (n=32)
Patient Isolate Period of
isolation
Genomovar
recA PCR
Epidemic
strain
marker
(esmR)
RAPD
typing
DNA
sequencing
of recA gene
B 2 B IIIA − 2 B. cenocepacia
C 3 B IIIA − 3 B. cenocepacia
D 4 A IIIA − 4 B. cenocepacia
D 5 B IIIA − 4 B. cenocepacia
E 6 A I − 5 B. cepacia
F 8 B IIIA − 7 B. cenocepacia
F 9 B IIIA − 7 B. cenocepacia
F 10 B IIIA − 7 B. cenocepacia
F 11 B IIIA − 7 B. cenocepacia
G 12 B V − 8 B. vietnamiensis
H 13 B IIIA − 9 B. cenocepacia
H 14 B IIIA − 9 B. cenocepacia
H 15 B IIIA − 9 B. cenocepacia
H 16 B IIIA − 10 B. cenocepacia
I 17 A V − 11 B. vietnamiensis
K 19 A IIIB + 13 B. cenocepacia
L 20 A II − 14 B. multivorans
L 21 A II − NP B. multivorans
L 22 B II − 14 B. multivorans
L 23 B II − 14 B. multivorans
L 24 B II − 14 B. multivorans
L 25 B II − 14 B. multivorans
M 26 B II − 15 B. multivorans
N 27 B IIIA + 16 B. cenocepacia
P 32 A IIIA − 18 B. cenocepacia
P 33 A IIIA − 18 B. cenocepacia
Q 34 B II − 19 B. multivorans
S 36 A II − 21 B. multivorans
S 37 B II − 21 B. multivorans
S 38 B II − 21 B. multivorans
S 39 B II − 21 B. multivorans
U 41 B IIIA − 23 B. cenocepacia
NP: not performed.
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2.1. Patients and samples
Samples identified as belonging to the B. cepacia complex in
the microbiology laboratory during two periods (regular use of
B. cepacia complex-selective medium) were studied: period A
(September 2000 to April 2001) and period B (June 2003 to June
2004). A total of 140 CF patients attended our unit during these
two periods, and the diagnosis of CF was based on international
consensus guidelines [12]. Respiratory samples were collected
from the patients during routine and unscheduled visits to
the outpatient clinic and cultured on selective media, including
B. cepacia complex-selective medium (Oxoid, Basingstoke,
United Kingdom). Plates were incubated at 36 °C for 18 to 96 h.
During the first period of the study (period A), bacteria
were identified using the Vitek automated system (bioMérieux
Vitek Inc., St. Louis, MO, USA), with additional biochemical
tests when indicated. During the second period of the study
(period B), bacterial identification was performed by classical
phenotypical testing.
The study was approved by the Ethics Committees of all
Institutions involved.
2.2. DNA purification and PCR
Isolates identified as B. cepacia complex were submitted to
DNA extraction as described elsewhere [8], and DNA was
quantified in an ultraviolet spectrophotometer (BioPhotometer
6131, Eppendorf AG, Hamburg, Germany).
The genomovar status of the B. cepacia complex isolates was
identified by sequential PCR targeting specific regions of the recA
gene as previously described [13–15]. Positive controls consist-
ing of DNA from the B. cepacia complex strain belonging to the
genomovar tested were included in all reactions.
Virulence markers were identified by PCR targeting the cblA
(cable pilus) and esmR (BCESM) genes as previously described
[6,7]. DNA from the B. cepacia complex strain AU0355 (epi-
demic strain expressing both virulence factors) was included in
the reactions as positive control.
After amplification, PCR products were visualized by elec-
trophoresis on 1.5% agarose gel stained with 0.5 mg/mL
ethidium bromide under UV illumination using an automated
system (AlphaImager®, Alpha Innotech Co., San Leandro,
California, USA). A negative control consisting of sample
without DNA was included in all reactions. All reactions were
carried out under a laminar flow UV hood according to standard
precautions to prevent PCR carry-over [16].
2.3. DNA sequencing
DNA sequencing of the recA gene was performed to confirm
the results of the specific PCR. DNA sequencing was carried
out using a panel of four primers (BCR 1–4) [13] and BUR1
and BUR2 primers [17], using the Big Dye Terminator kit
(Applied Biosystems Incorporation, Foster City, CA, USA)
in an automated DNA sequencer (ABI Prism 377, AppliedBiosystems). The results obtained were compared to sequences
deposited in the Genebank database using the BLAST program.
2.4. Molecular epidemiology (RAPD)
B. cepacia complex isolates were genotyped by the RAPD
method using primer 272 (5′-AGCGGGCCAA-3′), as pre-
viously described [18]. After amplification, the RAPD products
were visualized by electrophoresis on 7.5% acrylamide gel
stained with 0.2% silver nitrate. The results were interpreted by
direct visualization of the band patterns and isolates which
differed by two or more major bands were considered suf-
ficiently divergent to warrant separate strain designations.
3. Results
During the two periods of the study, a total of 672 respiratory
samples were obtained from 140 CF patients attending our CF
centre. B. cepacia complex isolates were identified by culture in
41 samples (35 sputum and 6 oropharyngeal swabs) from 21
Fig. 1. Genotyping of Burkholderia cepacia complex isolates. Acrylamide
(7.5%) gel stained with 0.2% silver nitrate. Each cluster of lanes corresponds to
isolates (identified by numbers) from one patient, identified by letter (contained
in Table 1).
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obtained in 32 isolates (4.7%), from 16 patients (11.4%).
B. cenocepacia was the most common genomovar identified
(17 isolates from 9 patients), followed by B. multivorans
(12 isolates from 4 patients). Two isolates were identified
as B. vietnamiensis and one as B. cepacia (genomovar I).
B. stabilis, B. dolosa and B. ambifaria were not identified
among the isolates. All isolates were unambiguously identified.
Patients who were positive during the first and second periods
kept the same genomovar for as long as 3 years.
DNA sequencing of the recA gene confirmed the PCR re-
sults of genomovar assignment for all 32 isolates of B. cepacia
complex. The nine samples with phenotypic misidentification
were tested by PCR using BUR1/2 primers and only seven
isolates tested positive. After DNA sequencing of these PCR
products, isolates were characterized as Burkholderia gladioli
(5 isolates) and Xanthomonas campestris (2 isolates). The other
two isolates remained unidentified.
Investigation of virulence markers showed that all isolates
were negative for the pilin gene (cblA), whereas two isolates
were positive for the epidemic strain marker gene (esmR), both
identified as B. cenocepacia.
Genotyping using RAPD detected 17 genotypes among 31
B. cepacia complex isolates. One B. cepacia complex iso-
late was not studied (isolate was lost), but it was obtained
from patient L who had 5 other isolates, all characterized as
B. multivorans and showing the same RAPD profile (Table 1).
Patients with two or more B. cepacia complex isolates during
the two study periods conserved the same genotype (Fig. 1)
and no identical patterns were identified among different pa-
tients. Only one patient presented the last of four isolates
of B. cenocepacia showing a different genotype (patient H,
isolate 16).4. Discussion
The present study shows that the distribution of genomovars
of the B. cepacia complex in our Institution is quite similar
to that observed elsewhere [19], with a predominance of
B. cenocepacia, followed by B. multivorans. The prevalence of
B. cepacia complex found was 11.4%, a significantly higher
rate than the 2.9% reported for the North American CF pop-
ulation [4]. Data regarding the prevalence of the B. cepacia
complex in Brazil are scarce, but a recent paper reported a
prevalence of 5.2% during a 10-year survey, although the
authors did not use selective medium [20].
There is also a lack of information concerning genomovar
distribution of B. cepacia complex isolates in Brazil, and a
well known inconsistent distribution throughout the world.
B. cenocepacia is the most common genomovar in Canada [21],
the United States [22] and Italy [3], but its prevalence may range
from 50% in the United States to 80% in Canadian CF centres.
However, data from Belgium [23] and France [24] indicate a
predominance of infections with B. multivorans. In Portugal,
recent data indicate a significant increase in the prevalence of
B. cepacia [25,26], maybe related to contamination of nasal
saline solutions [26]. One study combining CF and non-CF
B. cepacia complex isolates from Recife, Brazil, reported a high
prevalence of B. cenocepacia (72%) among non-CF isolates,
but the genomovar status was determined only in 5/11 CF
isolates, with B. cenocepacia and B. vietnamiensis accounting
for 2 isolates each and the other isolate assigned as B. cepacia
[9].
Microbiological culture identified 41 B. cepacia complex
isolates but this identity was confirmed in only 32 (78%) iso-
lates. Phenotypic identification of B. cepacia complex strains
is very difficult due to close similarities among these species
and related genera, and misidentifications have therefore been
reported [27,28].
Besides that, although B. cepacia-selective agar is an ex-
cellent culture medium for the isolation of B. cepacia complex
strains, other similar organisms, such as B. gladioli and Ral-
stonia spp., may also grow on this medium. Additional workup
of these 9 isolates misidentified by culture was performed
by PCR and DNA sequencing resulted positive in seven iso-
lates characterized as B. gladioli (5 isolates) and X. campestris
(2 isolates), while two isolates remained unidentified. These
two isolates may warrant future study using 16S rRNA gene
sequencing.
Molecular epidemiology using RAPD showed 100% con-
cordance with the results of genomovar determination, and
different patients did not share common genotypes. Previous
studies have shown that RAPD analysis presents a satisfactory
discriminatory power when compared to PFGE [18,29] and its
simplicity may favour its routine use for infection control in CF
centres.
In the present study, virulence markers were not identified in
a high proportion of isolates. This finding is in accordance with
the apparent lack of cross-infection among our patients, a sit-
uation markedly differing from that observed in other countries
such as Canada [21]. A previous Brazilian study of B. cepacia
339K.M. Martins et al. / Journal of Cystic Fibrosis 7 (2008) 336–339complex isolates has shown a higher prevalence of esmR (22/30
isolates) among B. cenocepacia isolates, but only two of these
isolates were obtained from CF patients and, interestingly, this
study also did not find any CF isolate positive for the cblA gene
[9].
In conclusion, the present study shows that B. cenocepacia is
the most prevalent member of the B. cepacia complex among
the CF patients studied here and cross-infection among patients
seems unlikely. The prevalence of virulence markers was very
low. We also observed that phenotypic misidentifications of
Burkholderia genus members may occur even when appropriate
microbiologic procedures are carefully followed and this find-
ing reinforces the need for the implementation of molecular
methods in microbiology laboratories involved in the care of CF
patients.
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